The activating mutations of FGFR3 have been shown to promote a positive feedback in FGFR3 expression through the stabilisation of Myc (Myc proto-oncogene protein), resulting in the upregulation of FGFR3 in bladder cancers [39]. This evidence concerns the gene FGFR3 and urinary bladder cancer.